医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fujifilm Announces New Platform in Digital Mammography Portfolio – Amulet Innovality* at RSNA 2013

2013年12月02日 AM01:25
このエントリーをはてなブックマークに追加


 

STAMFORD, Conn.

Today at the 99th annual meeting of the Radiological Society of North America (RSNA), FUJIFILM Corporation, Tokyo, Japan, introduced its latest and most innovative digital mammography system, the Amulet Innovality* in Chicago, IL. The Amulet Innovality is not commercially available in the United States. When it becomes available in the US it will be named the Aspire Cristalle**.

“Our newest full field digital mammography system is brilliantly designed to offer both 2D and advanced applications for the most confident diagnoses,” said David Hotchkiss, director of marketing, Women’s Health, CR, FUJIFILM Medical Systems U.S.A., Inc. “Now the radiologist can see breast tissue detail in a way that was never seen before in sharper, clearer images and can make confident diagnostic interpretations.”

Among the many new features of the Amulet Innovality**** is the ability of this system to utilize advanced applications which includes the ability to do breast tomosynthesis studies***. Since launching CR products, Fujifilm has demonstrated a commitment to introducing innovative, meaningful technology that will enable our customers to diagnose breast cancer earlier and save more lives. Fujifilm will continue to provide those breakthrough innovations as it increasingly invests in new approaches to breast imaging. The Amulet Innovality also has been designed to enhance patient comfort and the patient experience during annual exams.

To register for a product demonstration at RSNA, please visit http://rsna.fujimed.com. For every product demonstration registered online, Fujifilm will donate $25 to the National Breast Cancer Foundation. For more information about Fujifilm’s Aspire Breast Imaging Solutions, please visit: http://digital-mammography.fujimed.com.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From a broad selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information, please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. The company was among the top 10 companies around the world granted U.S. patents in 2012, and in the year ended March 31, 2013, had global revenues of $26.7 billion*. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

* At an exchange rate of 83 yen to the dollar.

*The Amulet Innovality is not commercially available in the United States

** The ASPIRE Cristalle will be made commercially available in the United States upon receipt of FDA clearance.

Caution: Investigational Device . Limited by U.S. Federal Law to Investigational Use.

***Tomosynthesis functionality for ASPIRE Cristalle is not commercially available in the United States.

****The Amulet Innovality will be known as Aspire Cristalle once available in the United States

CONTACT

Fujifilm
Lauren Geloso, 914-789-8303
lgeloso@fujifilm.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗